Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AGT | P01019 | 2/20 | 0.49 |
| ▸ | AGTR1 | P30556 | 3/20 | 0.47 |
| ▸ | AGTR2 | P50052 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9209176 | 0.95 | AGT (0.46) | AGTAGTR1AGTR2 | |
| SCHEMBL9024390 | 0.85 | AGT (0.48) | AGTAGTR1AGTR2 | |
| SCHEMBL9026501 | 0.84 | AGTR1 (0.54) | AGTAGTR1AGTR2 | |
| SCHEMBL1970464 | 0.81 | AGTR1 (0.56) | AGTAGTR1AGTR2 | |
| SCHEMBL9401993 | 0.81 | AGT (0.61) | AGTAGTR1AGTR2 | |
| SCHEMBL9025265 | 0.81 | AGTR1 (0.48) | AGTR1AGTR2 | |
| SCHEMBL8791066 | 0.80 | AGT (0.51) | AGTAGTR1AGTR2 | |
| SCHEMBL8791063 | 0.80 | AGT (0.52) | AGTAGTR1AGTR2 | |
| SCHEMBL9025990 | 0.80 | AGTR1 (0.53) | AGTAGTR1AGTR2 | |
| SCHEMBL9277565 | 0.80 | AGTR1 (0.47) | AGTAGTR1AGTR2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-5587390-A | Imidazole derivatives having a II antagonist activity | ISTITUTO LUSO FARMACO D'ITALIA S.P.A. (IT) | 1996-12-24 | — | — | US | disclosed |
| EP-0654030-B1 | IMIDAZOLE DERIVATIVES HAVING ANGIOTENSIN II ANTAGONIST ACTIVITY | LUSO FARMACO INST (IT) | 1996-12-18 | — | — | EP | disclosed |
| WO-1994003449-A1 | IMIDAZOLE DERIVATIVES HAVING A II ANTAGONIST ACTIVITY | ISTITUTO LUSO FARMACO D'ITALIA S.P.A. (IT) | 1994-02-17 | — | — | WO | disclosed |